Pfizer QI Grants for ALK-Positive Lung Cancer (Spain)

The Pfizer Quality Improvement Competitive Grant Program is offering funding for projects that aim to enhance the non-pharmacological management of adverse events and improve the quality of life for patients with ALK-positive non-small cell lung cancer (NSCLC) in Spain.

Who is Eligible?

Eligible applicants include medical institutions, nursing schools, healthcare organizations, professional associations, government agencies, and other entities involved in healthcare improvement. Projects may also involve collaborations between institutions as long as the requesting organization plays a key role and serves as the Project Lead.

Why It Matters

The ALK-positive NSCLC is treated with ALK tyrosine kinase inhibitors, which have significantly improved disease control and survival rates. However, managing adverse events associated with these treatments remains inconsistent across clinical settings, leading to avoidable treatment interruptions and negative impacts on patients’ quality of life. This grant aims to address gaps in non-pharmacological management, including education, patient monitoring, and supportive care pathways, to help optimize treatment outcomes and improve patient adherence.

Funding Details

• Grant Amount: Up to EUR 40,000 per project.

• Project Duration: Maximum of 18 months.

• Geographic Scope: Projects must be based in Spain.

• Application Deadline: April 9, 2026.

• Notification of Awards: May 2026.

• Project Start Date: July 31, 2026.

Eligible Project Activities

1. Educational Tools: Development of educational materials for patients, caregivers, and healthcare professionals to optimize management of adverse events.

2. Non-Pharmacological Strategies: Implementation of practical interventions to manage symptoms and improve quality of life, such as structured symptom monitoring and care coordination.

3. Monitoring Systems: Design and integration of patient-reported outcomes or digital tools to track patient symptoms and enhance clinical decision-making.

4. Supportive Care Pathways: Establishment of support pathways to ensure that patients receive comprehensive care tailored to their needs.

5. Barriers to Care: Identifying and addressing gaps in routine clinical practice and educational needs that prevent optimal care delivery.

Common Mistakes and Tips

• Inadequate Focus on Gaps in Current Practice: Ensure your proposal clearly addresses specific gaps in the management of adverse events and patient quality of life.

• Unclear Collaboration Roles: Clearly define the roles of all collaborators, ensuring that the Project Lead is appropriately identified as the main contact and driver of the project.

• Overly Ambitious Proposals: Ensure that the project scope is realistic within the 18-month timeframe and EUR 40,000 funding limit.

Frequently Asked Questions (FAQs)

1. What is the maximum grant amount available?

   • Projects can request up to EUR 40,000 in funding.

2. Who is eligible to apply for the grant?

   • Medical, nursing, allied health, and pharmacy professional schools, healthcare institutions, and professional organizations in Spain are eligible.

3. What is the duration of the grant?

   • The maximum project duration is 18 months.

4. What types of projects are eligible for funding?

   • Projects focused on non-pharmacological management of adverse events, patient education, monitoring, and supportive care pathways for ALK-positive NSCLC patients.

5. Can collaborations between institutions apply?

   • Yes, collaborations are encouraged as long as the requesting organization plays the key role and serves as the Project Lead.

Conclusion

The Pfizer Quality Improvement Competitive Grant Program is an excellent opportunity for organizations in Spain to improve the management of adverse events in ALK-positive non-small cell lung cancer. With up to EUR 40,000 in funding, this program aims to enhance the quality of life for patients through non-pharmacological interventions, educational tools, and supportive care pathways. If your organization is working on initiatives to improve cancer care and patient outcomes, this grant could provide crucial funding to help implement meaningful changes.